Navigation Links
ARCADIS' Jane Staveley to Moderate Congressional Briefing on Pharmaceuticals in Drinking Water
Date:9/14/2010

DENVER, Sept. 14 /PRNewswire/ -- Jane Staveley, a Principal Environmental Scientist for ARCADIS (EURONEXT: ARCAD), the international consultancy, design, engineering and management services company, will moderate a distinguished panel of experts on the topic of "Pharmaceuticals in Our Water: Concerns and Responses" during a briefing in the Rayburn House Office Building today, September 14. The briefing will be held from noon to 1:30 p.m. and is presented by the American Chemical Society's Science & the Congress Project, the Society for Risk Analysis and the Society of Toxicology, with honorary co-host, the House Science and Technology Committee.

(Logo:  http://photos.prnewswire.com/prnh/20090710/LA44654LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090710/LA44654LOGO)

With a focus on the presence of pharmaceuticals in waterways and drinking water throughout the United States, the briefing is designed to explore what is known about the relative contributions from different types of drugs, their persistence in the environment, and the best methods of drug disposal to reduce the amount getting into the environment.  

"I look forward to guiding the panelists in this important discussion as we explore what is known and still unknown about the potential impacts of water-borne pharmaceuticals on human health and ecological receptors," said Staveley. "We also will discuss what steps can be taken to maintain the health benefits of drugs, while at the same time mitigating any unintended consequences from their presence in our water."

Renowned scientists comprising the panel include Mae Wu from the Natural Resources Defense Council; Shane Snyder from the University of Arizona; Sierra Fletcher from the Product Stewardship Institute; and Richard Williams, formerly of Pfizer, Inc.

Staveley brings a wealth of knowledge to her role as moderator, given her more than 30 years of experience in both the public and private sectors working on myriad environmental issues. In addition to her role with ARCADIS, she is currently the President of the Society of Environmental Toxicology and Chemistry (SETAC) and is active in SETAC's advisory group on Pharmaceuticals in the Environment.

For more information, please contact Jeanna Blatt of ARCADIS at 303.471.3485 or Jeanna.Blatt@ARCADIS-US.com.

About ARCADIS:

ARCADIS is an international company providing consultancy, design, engineering and management services in infrastructure, water, environment and buildings. We enhance mobility, sustainability and quality of life by creating balance in the built and natural environment. ARCADIS develops, designs, implements, maintains and operates projects for companies and governments. With 15,000 employees and over $2.4 billion in revenues, the company has an extensive international network supported by strong local market positions. ARCADIS supports UN-HABITAT with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. Visit us at: www.arcadis-us.com.


'/>"/>
SOURCE ARCADIS
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
2. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
3. PTSD Associated With Higher Alzheimers/Dementia Risk; Moderate Alcohol Consumption May Lower it
4. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
5. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
6. New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
7. Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
8. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
9. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
10. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
11. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):